News

VolitionRx Limited Plans Upcoming Public Offering to Support Growth

VolitionRx Limited Plans Upcoming Public Offering to Support Growth

VolitionRx Limited Introduces Public Offering of Stock

VolitionRx Limited (NYSE AMERICAN: VNRX), a dynamic player in the epigenetics field, recently shared its plans to propose an underwritten public offering. This offering aims to sell common stock along with corresponding stock purchase warrants to potential investors. A significant aspect of this offering includes a 30-day option for the underwriter to acquire an additional 15% of the shares and warrants, subject to the public offering price minus discounts.

Utilization of Proceeds for Innovative Research

The funds generated from this offering are earmarked for various strategic purposes. Volition plans to channel these net proceeds towards advancing its research initiatives, facilitating product development, conducting clinical studies, and enhancing product commercialization. Additionally, these funds may be utilized for general corporate needs and to explore potential strategic acquisitions that align with Volition's long-term vision.

Working with Newbridge Securities Corporation

Newbridge Securities Corporation has been appointed as the exclusive book-running manager for this proposed offering. Their expertise will be key in navigating the complexities of the market to ensure a successful offering experience for all parties involved.

ROA and Compliance with SEC Regulations

This public offering is made possible through a "shelf" registration statement previously filed with the Securities and Exchange Commission (SEC). This registration, originally submitted on November 8, 2024, and later amended in 2025, simplifies the process for Volition to conduct this offering. Interested parties are encouraged to explore the offering terms detailed in the prospectus, which is readily available on the SEC's platform, providing insights into the specific conditions and characteristics associated with the potential offering.

Connecting with Investors

VolitionRx is committed to transparent communication with investors. For inquiries, individuals can contact Newbridge Securities Corporation directly to request additional information regarding the offering documentation and details. This aligns well with Volition's dedication to keeping its stakeholders informed and engaged throughout the investment process.

About Volition and Its Future Aspirations

Volition is a pioneering multi-national organization with a strong emphasis on advancing the science surrounding epigenetics. By focusing on early detection and monitoring of diseases, Volition strives to enhance both health outcomes and quality of life for individuals and their loved ones impacted by serious health issues.

Innovations in Disease Detection

One of the company's primary missions is to develop simple yet efficient blood tests that can aid in the detection and ongoing management of various health conditions, including several forms of cancer. This innovative approach could have a profound impact not only on patient longevity but also on their overall health journey.

Volition's Global Research Efforts

Based in Belgium, Volition fosters a rich research culture with innovation labs and facilities in the United States and London, ensuring a substantial global footprint. This enables the team to collaborate across borders, tapping into diverse expertise that contributes to their ongoing success in diagnostics and treatment options.

Media and Investor Relations Contacts

For media queries, you can reach out to Louise Batchelor at Volition, while inquiries related to investor relations can be directed to Jeremy Feffer from LifeSci Advisors. Both contacts are dedicated to assisting stakeholders and fostering a transparent dialogue about Volition's initiatives and progress.

Frequently Asked Questions

What is the purpose of Volition's public offering?

The public offering aims to raise funds for research, product development, and commercialization efforts.

Who is managing the public offering?

Newbridge Securities Corporation is the exclusive book-running manager for the offering.

How can investors learn more about the offering?

Investors can access detailed information via the prospectus filed with the SEC, available on their website.

What innovations is Volition working on?

Volition is developing blood tests aimed at early detection of diseases, particularly in cancer diagnostics.

Where is Volition based?

Volition operates from multiple locations, including Belgium, the United States, and London, enhancing its global research capacities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 31

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 196

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Why Recurring Lawn Bare Patches Need More Than Seed

Updated Category News Views 26

A bald spot beside a backyard gate is rarely asking for another fistful of seed. Scott Jungles, a residential landscape maintenance expert with Good Natured Gardening in Charleston, frames the issue plainly: recurring turf loss is often evidence that something below, above, or across that small section of lawn is working against the grass. That is a useful bit of...

Continue Reading
LNG’s Coming Glut Could Gut Global Trading Profits

Updated Category News Views 118

A five-year LNG surplus is the sort of forecast that makes people nod politely today and panic much too late. Bain & Company is putting a hard edge on that risk: the global trading profit pool could slide from an estimated $20 billion in 2026 to roughly $5.5 billion a year during a 2030–34 glut, then potentially tip below zero once cancellation costs bite. That is not a...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 106

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 57

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 11

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 12

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 46

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading

Top 5 Most Recently Viewed Articles

Portal26 Welcomes Rick O'Rourke as New Chief Revenue Officer

Updated Category News Views 222

Portal26 Appoints Rick O'Rourke as Chief Revenue Officer Portal26, a leading generative AI adoption management platform, has officially appointed Rick O'Rourke as its new Chief Revenue Officer (CRO). Bringing over 20 years of expertise, O'Rourke's impressive track record is well-aligned with the company’s mission to innovate and thrive within the rapidly-evolving...

Continue Reading
Biocodex Microbiota Foundation's $50K Grant Opens for 2026

Updated Category News Views 286

Let’s Talk Microbiome Research Had a look at this, huh? The Biocodex Microbiota Foundation is rolling out $50,000 for gut microbiome studies in 2026. They’re celebrating ten years of giving researchers a leg-up, with $500K dished out to date. It’s good stuff, depending on how you slice it. This isn’t just free cash; it’s a bid to push boundaries in health and...

Continue Reading
Discover Triple Paste's New Products for Healthy Skin

Updated Category News Views 119

Experience Healthy, Glowing Skin with Triple Paste The winter months can take a toll on our skin, especially for babies and new moms. Recognizing this, Advantice Health, the company behind the beloved Triple Paste® diaper rash ointments, is excited to reveal their latest additions designed to nurture and protect delicate skin. With a focus on safety and effectiveness,...

Continue Reading
Celebrating Sarah Valentini: A Trailblazer in Entrepreneurship

Updated Category News Views 633

Sarah Valentini: A Beacon of Innovation and Leadership In the ever-evolving landscape of entrepreneurship, recognition stands as a testament to ambition and dedication. This year marks a significant milestone as the Entrepreneur Of The Year program celebrates its 40th anniversary, highlighting leaders who are not only ambitious but are redefining the future with their...

Continue Reading
Future Outlook of the Asset Performance Management Market

Updated Category News Views 177

Asset Performance Management Market: Growth Projections The global Asset Performance Management Market is witnessing remarkable growth. The market size is expected to rise significantly, projecting an increase from approximately USD 2.16 billion to around USD 3.55 billion, reflecting a compound annual growth rate (CAGR) of 10.5% over the forecast period. This growth...

Continue Reading